The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-04-15 DOI:10.1111/dom.16366

Yifan Ren, Yuzhang Chen, Wenbin Zheng, Wen Kong, Yunfei Liao, Jiaoyue Zhang, Meng Wang, Tianshu Zeng

{"title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.","authors":"Yifan Ren, Yuzhang Chen, Wenbin Zheng, Wen Kong, Yunfei Liao, Jiaoyue Zhang, Meng Wang, Tianshu Zeng","doi":"10.1111/dom.16366","DOIUrl":null,"url":null,"abstract":"Aim: To investigate whether the antidiabetic agent glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can exert anti-inflammatory effects while lowering blood glucose, we performed a meta-analysis and systematic review.Methods: We searched 4 online databases (Medline, Embase, Cochrane Library and the Web of Science) for randomised controlled trials (RCTs) that examined changes after GLP-1RAs intervention in commonly accepted biomarkers of inflammation: C-reactive protein (CRP), tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), leptin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), monocyte chemotactic protein-1(MCP-1) and advanced glycation end products (AGEs).Results: This meta-analysis included 52 eligible RCTs (n = 4734) with a median follow-up of 24 weeks, a mean age of 54.13 years, 44.46% females, body mass index (BMI) 29.80 kg/m2, glycated haemoglobin (HbA1c) 8.28% and diabetes duration 7.27 years. GLP-1 RAs treatment, compared to placebo or conventional diabetes therapies (including oral medicine and insulin), resulted in significant reductions in CRP, TNF-α, IL-6, IL-1β and leptin (standard mean difference [SMD] -0.63 [-1.03, -0.23]; SMD -0.92 [-1.57, -0.27]; SMD -0.76 [-1.32, -0.20], SMD -3.89 [-6.56, -1.22], SMD -0.67 [-1.09, -0.26], respectively), as well as significant increases in adiponectin (SMD 0.69 [0.19, 1.19]).Conclusions: Our meta-analysis demonstrates that GLP-1 RAs exert significant anti-inflammatory effects in patients with T2DM. Our findings provide important insights that may guide the therapeutic application of GLP-1 RAs and inform the development of related therapies.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16366","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate whether the antidiabetic agent glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can exert anti-inflammatory effects while lowering blood glucose, we performed a meta-analysis and systematic review.

Methods: We searched 4 online databases (Medline, Embase, Cochrane Library and the Web of Science) for randomised controlled trials (RCTs) that examined changes after GLP-1RAs intervention in commonly accepted biomarkers of inflammation: C-reactive protein (CRP), tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), leptin, adiponectin, plasminogen activator inhibitor-1 (PAI-1), monocyte chemotactic protein-1(MCP-1) and advanced glycation end products (AGEs).

Results: This meta-analysis included 52 eligible RCTs (n = 4734) with a median follow-up of 24 weeks, a mean age of 54.13 years, 44.46% females, body mass index (BMI) 29.80 kg/m², glycated haemoglobin (HbA1c) 8.28% and diabetes duration 7.27 years. GLP-1 RAs treatment, compared to placebo or conventional diabetes therapies (including oral medicine and insulin), resulted in significant reductions in CRP, TNF-α, IL-6, IL-1β and leptin (standard mean difference [SMD] -0.63 [-1.03, -0.23]; SMD -0.92 [-1.57, -0.27]; SMD -0.76 [-1.32, -0.20], SMD -3.89 [-6.56, -1.22], SMD -0.67 [-1.09, -0.26], respectively), as well as significant increases in adiponectin (SMD 0.69 [0.19, 1.19]).

Conclusions: Our meta-analysis demonstrates that GLP-1 RAs exert significant anti-inflammatory effects in patients with T2DM. Our findings provide important insights that may guide the therapeutic application of GLP-1 RAs and inform the development of related therapies.

查看原文本刊更多论文

GLP-1受体激动剂对2型糖尿病患者循环炎症标志物的影响：系统回顾和荟萃分析

目的：探讨降糖药胰高血糖素样肽-1受体激动剂（glucagon-like peptide-1 receptor agonists, GLP-1 RAs）是否具有抗炎降糖的作用，并进行meta分析和系统评价。方法：我们检索了4个在线数据库（Medline、Embase、Cochrane Library和Web of Science），检索了随机对照试验（rct），这些试验检测了GLP-1RAs干预后常见炎症生物标志物的变化：c -反应蛋白（CRP）、肿瘤坏死因子-α (TNF-α)、白细胞介素-6 （IL-6）、白细胞介素-1β (IL-1β)、瘦素、脂联素、纤溶酶原激活物抑制剂-1（PAI-1）、单核细胞趋化蛋白-1（MCP-1）和晚期糖基化终产物（AGEs）。结果：本荟萃分析纳入52项符合条件的随机对照试验（n = 4734），中位随访时间为24周，平均年龄54.13岁，女性44.46%，体重指数（BMI） 29.80 kg/m2，糖化血红蛋白（HbA1c） 8.28%，糖尿病病程7.27年。与安慰剂或常规糖尿病治疗（包括口服药物和胰岛素）相比，GLP-1 RAs治疗导致CRP、TNF-α、IL-6、IL-1β和瘦素显著降低(标准平均差[SMD] -0.63 [-1.03, -0.23]；SMD -0.92 [-1.57, -0.27]；SMD为-0.76 [-1.32,-0.20]，SMD为-3.89 [-6.56,-1.22]，SMD为-0.67[-1.09,-0.26])，以及脂联素显著升高（SMD为0.69[0.19,1.19]）。结论：我们的荟萃分析表明，GLP-1 RAs在T2DM患者中具有显著的抗炎作用。我们的发现提供了重要的见解，可能指导GLP-1 RAs的治疗应用，并为相关疗法的发展提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.